Birgit Luber
Overview
Explore the profile of Birgit Luber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Sun N, Kunzke T, Shen J, Feuchtinger A, Wang Q, et al.
Br J Cancer
. 2024 Jan;
130(6):1036-1045.
PMID: 38267634
Background: Trastuzumab is the only first-line treatment targeted against the human epidermal growth factor receptor 2 (HER2) approved for patients with HER2-positive advanced gastric cancer. The impact of metabolic heterogeneity...
2.
Kolbe K, Haffner I, Schierle K, Maier D, Geier B, Luber B, et al.
J Cancer Res Clin Oncol
. 2022 Aug;
149(3):1319-1329.
PMID: 36030286
Purpose: The prospective multicenter VARIANZ study aimed to identify resistance biomarkers for HER2-targeted treatment in advanced gastric and esophago-gastric junction cancer (GC, EGJC). HER2 test deviations were found in 90...
3.
Wang J, Kunzke T, Prade V, Shen J, Buck A, Feuchtinger A, et al.
Clin Cancer Res
. 2022 Apr;
28(13):2865-2877.
PMID: 35395077
Purpose: Current systems of gastric cancer molecular classification include genomic, molecular, and morphological features. Gastric cancer classification based on tissue metabolomics remains lacking. This study aimed to define metabolically distinct...
4.
Ebert K, Haffner I, Zwingenberger G, Keller S, Raimundez E, Geffers R, et al.
BMC Cancer
. 2022 Mar;
22(1):254.
PMID: 35264144
Background: The standard treatment for patients with advanced HER2-positive gastric cancer is a combination of the antibody trastuzumab and platin-fluoropyrimidine chemotherapy. As some patients do not respond to trastuzumab therapy...
5.
Kunzke T, Holzl F, Prade V, Buck A, Huber K, Feuchtinger A, et al.
Clin Transl Med
. 2021 Sep;
11(9):e547.
PMID: 34586736
No abstract available.
6.
Haffner I, Schierle K, Raimundez E, Geier B, Maier D, Hasenauer J, et al.
J Clin Oncol
. 2021 Mar;
39(13):1468-1478.
PMID: 33764808
Purpose: Trastuzumab is the only approved targeted drug for first-line treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic gastric cancer (mGC). However, not all patients respond and most...
7.
Ebert K, Zwingenberger G, Barbaria E, Keller S, Heck C, Arnold R, et al.
BMC Cancer
. 2020 Nov;
20(1):1127.
PMID: 33225928
An amendment to this paper has been published and can be accessed via the original article.
8.
Ebert K, Zwingenberger G, Barbaria E, Keller S, Heck C, Arnold R, et al.
BMC Cancer
. 2020 Oct;
20(1):1039.
PMID: 33115415
Background: Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer death worldwide. The molecular mechanisms of action for anti-HER-family drugs in gastric cancer...
9.
Prade V, Kunzke T, Feuchtinger A, Rohm M, Luber B, Lordick F, et al.
Mol Metab
. 2020 Apr;
36:100953.
PMID: 32278304
Background: Imaging mass spectrometry enables in situ label-free detection of thousands of metabolites from intact tissue samples. However, automated steps for multi-omics analyses and interpretation of histological images have not...
10.
Raimundez E, Keller S, Zwingenberger G, Ebert K, Hug S, Theis F, et al.
PLoS Comput Biol
. 2020 Mar;
16(3):e1007147.
PMID: 32119655
Targeted cancer therapies are powerful alternatives to chemotherapies or can be used complementary to these. Yet, the response to targeted treatments depends on a variety of factors, including mutations and...